OR WAIT null SECS
EVERSANA, a provider of global commercial services to the life sciences industry, today announced a partnership with the Institute for Clinical and Economic Review (ICER) to advance standards for the usage of transparent, replicable and robust indirect treatment comparisons in health technology assessments.
ICER is an independent nonprofit research institute that produces influential drug assessments and other reviews on the comparative clinical effectiveness and cost-effectiveness of health care interventions. ICER will use EVERSANA’s proprietary technology as the preferred platform for conducting indirect treatment comparisons to obtain comparative effectiveness data in the absence of head-to-head clinical trials. The organization began testing EVERSANA’s data analytics and evidence synthesis platform in early 2020.
For more information, click here.